Podocyte involvement in lupus nephritis based on the 2003 ISN/RPS system: A large cohort study from a single centre

Rheumatology (United Kingdom)

Volumn 53, Issue 7, 2014, Pages 1235-1244

  Wang, Yan ^a,b,c,d   Yu, Feng ^a,b,c,d   Song, Di ^a,b,c,d   Wang, Su Xia ^a,b,c,d   Zhao, Ming Hui ^a,b,c,d,e  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b PEKING UNIVERSITY   (China)

^c BEIJING HOSPITAL   (China)

^d BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^e Tsinghua University   (China)

Author keywords

Foot process width; Lupus nephritis; Podocyte; SLE

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN A; LEFLUNOMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

2003 INTERNATIONAL SOCIETY OF NEPHROLOGY AND RENAL PATHOLOGY SOCIETY; ADULT; ARTICLE; CELL DAMAGE; CELL STRUCTURE; CELLULAR PARAMETERS; CLINICAL ASSESSMENT; CLINICAL FEATURE; COHORT ANALYSIS; CORRELATIONAL STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; FOOT PROCESS WIDTH; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY BIOPSY; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; NEPHROTIC SYNDROME; OUTCOME ASSESSMENT; PODOCYTE; PRIORITY JOURNAL; REFERENCE VALUE; REMISSION; RENAL SYSTEM PARAMETERS; RETROSPECTIVE STUDY;

FOOT PROCESS WIDTH; LUPUS NEPHRITIS; PODOCYTE; SLE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CHINA; COHORT STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; LUPUS NEPHRITIS; MALE; MIDDLE AGED; PODOCYTES; PROTEINURIA; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84902954485     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ket491     Document Type: Article

References (47)

1. Shankland SJ. The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int 2006;69:2131-47.
2. Trivedi S, Zeier M, Reiser J. Role of podocytes in lupus nephritis. Nephrol Dial Transplant 2009;24:3607-12.
3. Kraft SW, Schwartz MM, Korbet SM et al. Glomerular podocytopathy in patients with systemic lupus erythematosus. J Am Soc Nephrol 2005;16:175-9.
4. Horino T, Takao T, Morita T et al. Minimal change nephrotic syndrome associated with systemic lupus erythematosus. Nephrol Dial Transplant 2006;21:230.
5. Hertig A, Droz D, Lesavre P et al. SLE and idiopathic nephrotic syndrome: coincidence or not? Am J Kidney Dis 2002;40:1179-84.
6. Horita Y, Nazneen A, Cheng M et al. A case of systemic lupus erythematosus associated with minimal change nephrotic syndrome. Nihon Jinzo Gakkai Shi 1997;39:759-64.
7. Makino H, Haramoto T, Shikata K et al. Minimal-change nephrotic syndrome associated with systemic lupus erythematosus. Am J Nephrol 1995;15:439-41.
8. Papo T, Faucher C, Huong DL et al. Idiopathic focal segmental glomerulosclerosis in a patient with systemic lupus erythematosus: an unusual combination. Am J Kidney Dis 1994;24:880-1.
9. Okai T, Soejima A, Suzuki M et al. A case report of lupus nephritis associated with minimal change nephrotic syndrome-comparison of various histological types of 67 cases with lupus nephritis. Nihon Jinzo Gakkai Shi 1992;34:835-40.
10. Matsumura N, Dohi K, Shiiki H et al. Three cases presenting with systemic lupus erythematosus and minimal change nephrotic syndrome. Nihon Jinzo Gakkai Shi 1989;31:991-9.
11. Han TS, Schwartz MM, Lewis EJ. Association of glomerular podocytopathy and nephrotic proteinuria in mesangial lupus nephritis. Lupus 2006;15:71-5.
12. Shea-Simonds P, Cairns TD, Roufosse C et al. Lupus podocytopathy. Rheumatology 2009;48:1616-8.
13. Gutierrez S, Petiti JP, De., Paul AL et al. Lupus-related podocytopathy Could it be a new entity within the spectrum of lupus nephritis?. Nefrologia 2012;32:245-6.
14. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40: 1725.
15. Liang MH, Socher SA, Larson MG et al. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989;32:1107-18.
16. Bombardier C, Gladman DD, Urowitz MB et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
17. Wang HY, Cui TG, Hou FF et al. Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study. Lupus 2008;17:638-44.
18. Chan TM, Tse KC, Tang CS et al. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus 2005;14:265-72.
19. Ginzler EM, Wofsy D, Isenberg D et al. Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. Arthritis Rheum 2010;62:211-21.
20. Weening JJ, D'Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004;15:241-50.
21. Austin HA III, Boumpas DT, Vaughan EM et al. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int 1994;45:544-50.
22. Austin HA III, Muenz LR, Joyce KM et al. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 1984;25:689-95.
23. Gundersen HJ, Seefeldt T, Osterby R. Glomerular epithelial foot processes in normal man and rats. Distribution of true width and its intra-and inter-individual variation. Cell Tissue Res 1980;205:147-55.
24. van den Berg JG, van den Bergh Weerman MA, Assmann KJ et al. Podocyte foot process effacement is not correlated with the level of proteinuria in human glomerulopathies. Kidney Int 2004;66:1901-6.
25. Fleiss JL, ed. The Measurement of Interrater Agreement. New York: John Wiley & Sons, 1981.
26. Grootscholten C, Bajema IM, Florquin S et al. Interobserver agreement of scoring of histopathological characteristics and classification of lupus nephritis. Nephrol Dial Transplant 2008;23:223-30.
27. Rezende GM, Viana VST, Malheiros DM. Podocyte injury in pure membranous and proliferative lupus nephritis: distinct underlying mechanisms of proteinuria? Lupus 2013, Advance Access published 19 December 2013, doi:10.1177/0961203313517152.
28. Masutani K, Akahoshi M, Tsuruya K et al. Predominance of Th1 immune response in diffuse proliferative lupus nephritis. Arthritis Rheum 2001;44:2097-106.
29. Mason LJ, Ravirajan CT, Rahman A et al. Is alpha-actinin a target for pathogenic anti-DNA antibodies in lupus nephritis? Arthritis Rheum 2004;50:866-70.
30. Desai N, Cimbaluk D, Lewis E et al. Proteinuria in membranous lupus nephritis: the pathology is in the podocyte. Lupus 2013;22:461-8.
31. Beck LH Jr, Bonegio RG, Lambeau G et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009;361:11-21.
32. Debiec H, Guigonis V, Mougenot B et al. Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. N Engl J Med 2002;346:2053-60.
33. Austin HA, Illei GG. Membranous lupus nephritis. Lupus 2005;14:65-71.
34. Baker PJ, Ochi RF, Schulze M et al. Depletion of C6 prevents development of proteinuria in experimental membranous nephropathy in rats. Am J Pathol 1989;135:185-94.
35. Schulze M, Donadio JV Jr, Pruchno CJ et al. Elevated urinary excretion of the C5b-9 complex in membranous nephropathy. Kidney Int 1991;40:533-8.
36. Mashmoushi AK, Hofbauer AF, Gilkeson GS et al. Role of nitric oxide in podocyte physiology in lupus nephritis. Free Radic Biol Med 2012;53:S76-7.
37. Igawa T, Nakashima H, Sadanaga A et al. Deficiency in EBV-induced gene 3 (EBI3) in MRL/lpr mice results in pathological alteration of autoimmune glomerulonephritis and sialadenitis. Mod Rheumatol 2009;19:33-41.
38. Shimizu S, Sugiyama N, Masutani K et al. Membranous glomerulonephritis development with Th2-type immune deviations in MRL/lpr mice deficient for IL-27 receptor (WSX-1). J Immunol 2005;175:7185-92.
39. Shalhoub RJ. Pathogenesis of lipoid nephrosis: a disorder of T-cell function. Lancet 1974;2:556-60.
40. Clement LC, Avila-Casado C, Mace C et al. Podocytesecreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome. Nat Med 2011;17:117-22.
41. Wei C, El., Hindi S, Li J et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 2011;17:952-60.
42. Lo MS, Tsokos GC. Tcells in systemic lupus erythematosus: progress toward targeted therapy. Rheumatologist 2011 (August). http://www.the-rheumatologist.org/details/article/1311767/T_Cells_in_Systemic_Lupus_ Erythematosus.html (5 February 2014, date last accessed).
43. Salvatore SP, Barisoni LM, Herzenberg AM et al. Collapsing glomerulopathy in 19 patients with systemic lupus erythematosus or lupus-like disease. Clin J Am Soc Nephrol 2012;7:914-25.
44. Faul C, Donnelly M, Merscher-Gomez S et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 2008;14:931-8.
45. Mathieson PW. Proteinuria and immunity-an overstated relationship? N Engl J Med 2008;359:2492-4.
46. Austin HA III, Illei GG, Braun MJ et al. Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. J Am Soc Nephrol 2009;20:901-11.
47. Bao H, Liu ZH, Xie HL et al. Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol 2008;19:2001-10.